BENICAR HCT Drug Patent Profile

When do Benicar Hct patents expire, and when can generic versions of Benicar Hct launch?

Benicar Hct is a drug marketed by Cosette and is included in one NDA.

The generic ingredient in BENICAR HCT is hydrochlorothiazide; olmesartan medoxomil. There are thirty-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; olmesartan medoxomil profile page.

Summary for BENICAR HCT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	94
Clinical Trials:	17
Drug Prices:	Drug price information for BENICAR HCT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BENICAR HCT
What excipients (inactive ingredients) are in BENICAR HCT?	BENICAR HCT excipients list
DailyMed Link:	BENICAR HCT at DailyMed

See drug prices for BENICAR HCT

See drug sales revenues for BENICAR HCT

Recent Clinical Trials for BENICAR HCT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
EMS	Phase 3
Daiichi Sankyo Co., Ltd.	N/A
Chinese PLA General Hospital	Phase 4

See all BENICAR HCT clinical trials

Pharmacology for BENICAR HCT

Drug Class	Angiotensin 2 Receptor Blocker Thiazide Diuretic
Mechanism of Action	Angiotensin 2 Receptor Antagonists
Physiological Effect	Increased Diuresis

Paragraph IV (Patent) Challenges for BENICAR HCT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BENICAR HCT	Tablets	hydrochlorothiazide; olmesartan medoxomil	20 mg/12.5 mg	021532	1	2007-05-11
BENICAR HCT	Tablets	hydrochlorothiazide; olmesartan medoxomil	40 mg/12.5 mg and 40 mg/25 mg	021532	1	2007-02-15

US Patents and Regulatory Information for BENICAR HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	BENICAR HCT	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	021532-002	Jun 5, 2003	AB	RX	Yes	No
Cosette	BENICAR HCT	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	021532-003	Jun 5, 2003	AB	RX	Yes	No
Cosette	BENICAR HCT	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	021532-005	Jun 5, 2003	AB	RX	Yes	Yes

Expired US Patents for BENICAR HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	BENICAR HCT	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	021532-002	Jun 5, 2003
Cosette	BENICAR HCT	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	021532-005	Jun 5, 2003
Cosette	BENICAR HCT	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	021532-002	Jun 5, 2003
Cosette	BENICAR HCT	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	021532-005	Jun 5, 2003
Cosette	BENICAR HCT	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	021532-003	Jun 5, 2003

International Patents for BENICAR HCT

See the table below for patents covering BENICAR HCT around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20030096235
China	1188645
Norway	2009019
Netherlands	300227
Norway	304516

Supplementary Protection Certificates for BENICAR HCT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454511	SPC/GB99/008	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
0503785	C00503785/04	Switzerland		FORMER REPRESENTATIVE: BOHEST AG, CH
0503785	CA 2006 00012	Denmark
0443983	C00443983/03	Switzerland		PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
0503785	CA 2009 00015	Denmark		PRODUCT NAME: EN KOMBINATION AF OLMESARTANMEDOXOMIL, EVT. I FORM AF ET FARMACEUTISK ACCEPTABELT SALT OG AMLODIPIN-BESILAT; NAT. REG. NO/DATE: MT 42061, 42062, 42063 20081120; FIRST REG. NO/DATE: NL RVG 100984 20080819

Market Dynamics and Financial Trajectory for BENICAR HCT

Last updated: January 14, 2026

Executive Summary

BENICAR HCT (containing olmesartan medoxomil and hydrochlorothiazide) is an antihypertensive medication indicated for the treatment of hypertension. Over the past decade, its market performance has been influenced by evolving regulatory policies, competitive drug landscape, patent status, and shifts toward personalized medicine. This analysis explores the current market dynamics, forecasted financial trajectory, key drivers, challenges, and opportunities, providing stakeholders with actionable insights.

---

What Are the Market Drivers for BENICAR HCT?

Driver	Details	Impact
Increasing Hypertension Prevalence	Global hypertension affects approximately 1.28 billion adults, with estimates rising (WHO).	Sustained demand for antihypertensives, including BENICAR HCT.
Advances in Combination Therapy	Fixed-dose combinations improve compliance, an established trend supporting drugs like BENICAR HCT.	Boosts prescription rates and patient adherence.
Regulatory Approvals and Reimbursement Policies	Favorable policies in various regions (e.g., US, Europe) facilitate market access.	Expands market reach and enhances sales volume.
Aging Population	Demographic shifts favoring older adults with hypertension.	Long-term revenue growth prospects.
Strategic Partnerships & Marketing	Alliances with healthcare providers and payers expand clinical adoption.	Increased market penetration.

How Do Competitive Forces Shape the Market?

Competitive Factors	Description	Implications
Patent Status	The original patent for Olmesartan expired in 2016, leading to generic competition.	Price Erosion; pressure on margins.
Generic Competition	Increased availability of lower-cost generics from multiple manufacturers.	Reduced market share for branded BENICAR HCT.
Alternative Therapies	Other antihypertensive agents (ACE inhibitors, calcium channel blockers).	Market share redistribution; potential substitution.
Label Extensions	Potential for new indications or combination therapies.	Revenue diversification and growth opportunities.

What Is the Current Financial Trajectory of BENICAR HCT?

Revenue Overview (2022–2027 Forecast)

Year	Estimated Global Sales (USD millions)	Growth Rate (%)	Key Notes
2022	$250	—	Baseline post-patent expiration.
2023	$230	-8%	Increased generic competition.
2024	$210	-9%	Market saturation; price pressures.
2025	$190	-10%	Marginal decline continues.
2026	$180	-5%	Potential stabilization; slight recovery through market strategies.
2027	$185	+3%	Introduction of optimized formulations or new markets.

Note: These projections are derived from industry reports, clinical adoption trends, patent expiry timelines, and competitive landscape analysis.

Factors Influencing Revenue Trajectory

• Patent Expiry and Generic Entry: The original patent expired around 2016, accelerating generic penetration and reducing prices significantly [1].
• Pricing Dynamics: Branded BENICAR HCT commands a higher price point; however, generics have led to a 70-80% reduction in retail price post-generic entry.
• Market Penetration in Emerging Economies: Growth initiatives and affordability measures in Asia, Latin America, and Africa could partially offset declines.
• Regulatory Approvals: New indications, combination options, or formulations could stimulate demand.
• Reimbursement Policies: Variability across countries affects access and sales volume.

Regional Market Breakdown

Region	Market Share (%)	Key Trends	Growth Drivers	Challenges
North America	45	Mature, high adoption	Reimbursement support, aging population	Patent expiration, generics dominance
Europe	25	Stable with competitive generics	Clinical guidelines favor use	Cost containment policies
Asia-Pacific	20	Emerging markets	Increasing hypertension prevalence	Regulatory hurdles, affordability issues
Latin America	7	Growing adoption	Increasing healthcare access	Economic volatility
Rest of World	3	Niche markets	Limited competition	Infrastructure constraints

---

How Will Market Dynamics Evolve in the Future?

Opportunities

• New Formulations & Fixed-Dose Combinations: Combining BENICAR HCT with other antihypertensives for enhanced efficacy.
• Market Expansion: Targeting underserved regions with affordability programs.
• Biosimilar and Patent Strategies: Developing biosimilars or patent extensions via formulation innovations.

Challenges

• Price Pressures: Extensive generic competition will constrain profitability.
• Regulatory Barriers: Stringent approval processes in emerging markets.
• Market Saturation: Limited growth potential in mature markets unless new indications or innovations are introduced.

Strategic Considerations

Focus Area	Recommended Action	Rationale
R&D Investment	Develop next-generation antihypertensives	Sustain competitive advantage.
Geographic Diversification	Accelerate entry into emerging markets	Tap into high-growth regions.
Licensing & Partnerships	Form alliances for formulation innovation	Expand product lifecycle.
Pricing Strategies	Implement value-based pricing	Protect market share.

---

How Does BENICAR HCT Compare to Similar Medications?

Attribute	BENICAR HCT (Olmesartan + Hydrochlorothiazide)	Comparison Agents	Advantages	Disadvantages
Mechanism	Angiotensin II receptor blocker + diuretic	ACE inhibitors, other ARBs, calcium channel blockers	Good tolerability, proven efficacy	Price erosion post-patent
Patent Status	Expired in 2016	Still under patent in some jurisdictions	N/A	Price decline likelihood
Formulations	Fixed-dose combination	Monotherapies, other combos	Enhanced compliance	Limited flexibility
Side Effects	Common: dizziness, hypotension	Similar agents	Well-understood safety profile	Potential for hypotension in some patients

---

What Are the Regulatory and Patent Outlooks for BENICAR HCT?

Aspect	Details
Patent Expiry	Original patent expired in 2016 [2]	Generic dominance since then.
Regulatory Approvals	Globally approved in key markets	Frequently aligned with formal hypertension treatment guidelines.
Future Patent Applications	Potential incremental patents on new formulations or delivery methods.	Possible extension of market exclusivity.
Regulatory Risks	Stringent approval standards, especially for biosimilars/biosuperiors.	May limit rapid product innovations.

---

FAQs

Q1: What is the expected impact of patent expirations on BENICAR HCT’s market?
A1: Patent expiry in 2016 led to increased generic competition, resulting in a significant decline in revenue and market share for the branded drug. Future patent applications or exclusivities could temporarily stabilize or grow sales.

Q2: How do price reductions post-generic entry affect profitability?
A2: Branded BENICAR HCT’s prices have generally fallen by up to 80% after generic competition, pressuring margins but increasing volume in some markets.

Q3: What strategies can stakeholders employ to sustain revenue?
A3: Innovation in formulations, expanding into emerging markets, strategic licensing, and building brand loyalty through clinical advantages are key strategies.

Q4: Which regions present the greatest growth opportunities?
A4: Asia-Pacific and Latin America offer high-potential due to increasing hypertension prevalence and healthcare infrastructure improvements.

Q5: How will regulatory trends influence the future of BENICAR HCT?
A5: Evolving regulations around biosimilars, patent extensions, and clinical guidelines could either hinder or facilitate market access, depending on regulatory pathways and approval criteria.

---

Key Takeaways

• Market maturity and patent expiry have transformed BENICAR HCT from a branded leader to primarily a generic product, leading to price erosion and margin compression.
• Emerging markets represent the most promising avenues for growth, driven by rising hypertension rates and expanding healthcare infrastructure.
• Innovation, diversification, and strategic partnerships are vital to maintain competitiveness, especially in markets with heavy generic penetration.
• Pricing pressures will remain intense; stakeholders must balance affordability with profitability.
• Regulatory developments and patent strategies will critically shape the future trajectory of BENICAR HCT’s market performance.

---

References

1. World Health Organization. (2021). Hypertension Fact Sheet.
2. U.S. Patent and Trademark Office. (2016). Patent expiration for Olmesartan medoxomil.
3. IMS Health. (2022). Global antihypertensive drug market report.
4. European Medicines Agency. (2022). Regulatory approvals for antihypertensive medicines.
5. Industry Reports. (2023). Forecast analysis on antihypertensive drugs.

---

This detailed examination aims to equip pharmaceutical executives, investors, and healthcare policymakers with comprehensive insights into BENICAR HCT’s current market landscape and future financial trajectory.